1 / 16

Adaptive Clinical Trial Designs: Health Canada’s Regulatory Perspective

Adaptive Clinical Trial Designs: Health Canada’s Regulatory Perspective. Celia Lourenco, PhD Bureau of Gastroenterology, Infection And Viral Diseases. Health Canada - HPFB.

sbirney
Download Presentation

Adaptive Clinical Trial Designs: Health Canada’s Regulatory Perspective

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Adaptive Clinical Trial Designs: Health Canada’s Regulatory Perspective Celia Lourenco, PhD Bureau of Gastroenterology, Infection And Viral Diseases

  2. Health Canada - HPFB • Reviews and authorises clinical trial applications for pharmaceuticals, biologics, radiopharmaceuticals, medical devices, and natural health products • Reviews and authorises for sale pharmaceuticals, biologics, radiopharmaceuticals, medical devices, and natural health products • Carries out pharmacovigilance in clinical trials and post-market

  3. Main regulatory concerns • Design should be appropriate to answer the scientific question of interest • Sponsor must demonstrate control of Power and Type I error rate over the entire clinical trial • Operational bias – appropriate pre-planning and measures are implemented to avoid operational bias (e.g., randomization, blinding, secure electronic systems, independent DSMBs, blinded steering committees, etc.)

  4. Adaptive Designs • On Health Canada’s radar for several years (HC working group formed in 2008) • Many seen in clinical trial applications (CTAs) • Some in new drug submissions (NDSs)

  5. HC WG definition of adaptive design • An adaptive clinical trial design is a study design planned prospectively that uses accumulating data to decide how to modifyaspects of an ongoing study and that uses pre-specified, validated, methodological approaches to preserve the validity and integrity of the trial

  6. Some examples in CTAs • Adaptive randomization, drop or add arms • Mainly in phase 2 trials • Use of modeling and simulation • Sample size re-estimation: phase 2 or 3 • Seamless design: phase 2/3, two-stage dose selection

  7. Some examples in NDSs • Indacaterol: for treatment of COPD - Trial B2335S, a 26-week seamless adaptive design trial that included an initial 2 week dose-ranging phase • Gardasil 9: a vaccine indicated for the prevention of infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 • A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Women

  8. B2335s Trial Design

  9. Gardasil 9 design • From FDA’s review on FDA’s website: • Phase 2b/3, with two parts • Part A: ~1240 subjects were enrolled, equally randomized to 3 dose formulations of 9vHPV or qHPV • Part B: one dose formulation of 9vHPV was selected for Part B based on interim immunogenicity results, with ~13,380 subjects enrolled in Part B and equally randomized to the selected dose formulation of 9vHPV or qHPV

  10. Conclusion from case-studies • Adaptive designs present increased complexity • May be difficult to interpret, and make use of new statistical tests/procedures • Increase in use of Bayesian statistics, which involves a different approach in statistical inference • Increase use of simulation – time consuming to validate and can be difficult to interpret what the results mean

  11. Why and What of Simulation • Simulation provides the operating characteristics of the trial design • That is the description (a picture) of the likelihood (probabilities) of how the trial will progress down the different paths (planned possible adaptations) to eventual completion or termination of the trial

  12. Seeing that Picture • The sponsors should provide that picture • Usually in well designed and planned trials, yes • The question is should regulators look behind the picture and actually check that it was done right? • That means try to duplicate the simulation results • Ask to submit codes, and check/replicate

  13. Conclusions & recommendations • Continue to monitor adaptive designs, expect that the topic will continue to evolve • Pre-submission meetings are encouraged • Optimize biostatistics and IT resources to deal with emerging trends such as use of Bayesian statistics • Provide support and encourage attendance of courses and seminars on adaptive design • Biostatistics consult sought (early) for pivotal Adaptive Design trials in submissions

  14. THANK YOU!

More Related